Dr. Casey Wang, MD

Dr. Wang practices at Bellaire Dermatology Associates, P.a. in Bellaire, Texas.

Dr. Wang's NPI, 1295172823, was assigned on May 22, 2013. Dr. Wang holds Texas license Q1050.

Dr. Wang's primary practice is Bellaire Dermatology Associates, P.a., at 6565 W Loop S Suite 800 Suite 800, Bellaire, TX 77401-3500. The practice phone is (713) 661-4383.

Dr. Wang's primary practice is Bellaire Dermatology Associates, P.a. in Bellaire, Texas. The medical group on file is Bellaire Dermatology.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wang practices. Vendor and product names are available with a free account.

Dermatology is Dr. Wang's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Wang is licensed in Texas.

CMS data shows 1,266 Medicare services from Dr. Wang across 14 procedure codes in 2024, for 356 Medicare patients. Medicare paid $59,961 for them. Every service was in an office.

CMS counts 356 Medicare patients who saw Dr. Wang in 2024. The largest group is 65 to 74, with 189 patients. 75% of them have high cholesterol, and 65% have high blood pressure. Their average risk score is 0.95, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Wang's median patient age at 56, with 55% women.

In 2024, Dr. Wang wrote 437 Medicare Part D claims for 205 patients. 91% of them were for generic drugs. CMS names the drug for 262 of them, across 9 drugs with 11 or more claims each, at $6,711 in total drug cost. In 2023, CMS named 453 claims across 16 drugs.

Dr. Wang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 469 procedures of removal of skin lesions by Dr. Wang, more than 86% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 7 papers to Dr. Wang, published from 2013 to 2017. 2016 was the busiest year, with 3. The most frequent topics are Mycosis Fungoides and Skin Neoplasms. Dr. Wang's most frequent co-authors are Madeleine Duvic, MD, Nnenna Gebechi Agim, MD and Paul R. Bergstresser, MD.

CMS Open Payments shows 444 general payments to Dr. Wang from 31 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 50% of the total. Incyte Corporation paid the most, $6,518. It also lists 12 research payments totaling $2,492 from 2016 to 2024, naming 2 clinical trials.